MRKR Form 4: 147,611 director options, $0.9877 strike, 36-month vest

Rhea-AI Filing Summary

Marker Therapeutics (MRKR) filed a Form 4 reporting a director stock option grant. The filing shows a stock option (right to buy) for 147,611 shares at an exercise price of $0.9877, granted on 10/31/2025 under the company’s 2020 Omnibus Stock Ownership Plan. The options vest in 36 equal monthly installments, subject to continued board service, and expire on 10/31/2035. Following the transaction, 147,611 derivative securities are beneficially owned, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Corzo Kathryn Penkus

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	147,611	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 147,611 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corzo Kathryn Penkus

(Last) (First) (Middle)

MARKER THERAPEUTICS, INC.

2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Marker Therapeutics, Inc. [ MRKR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.9877	10/31/2025		A		147,611		(1)	10/31/2035	Common Stock	147,611	$0	147,611	D

Explanation of Responses:

1. Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. The shares vest equally over thirty six (36) monthly installments, subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, October 31, 2025.

	/s/ Julio C. Esquivel as Attorney-In-Fact for Kathryn Penkus Corzo	11/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Marker Therapeutics (MRKR) report on this Form 4?

A director stock option grant for 147,611 shares at an exercise price of $0.9877, granted on 10/31/2025.

What is the vesting schedule for the MRKR director’s options?

They vest in 36 equal monthly installments, contingent on continued service as a director.

When do the reported MRKR options expire?

The options expire on 10/31/2035.

Under which plan were the MRKR options granted?

They were granted under the company’s 2020 Omnibus Stock Ownership Plan.

How many derivative securities are beneficially owned after this transaction?

147,611 derivative securities are beneficially owned following the transaction.

What is the ownership form for the reported MRKR options?

The options are held directly.